Quantity of qualified clients: CDEC discussed the uncertainty in the number of individuals with moderately severe to serious hemophilia B in Canada eligible for etranacogene dezaparvovec. Scientific industry experts consulted by CADTH indicated that some people who will be labeled as acquiring delicate or reasonable illness might have a serious ble